{
  "id": 8985740,
  "title": "Beacon eye gene therapy hits mark in late-stage study",
  "url": "https://urgent.news/2026/09/21/beacon-eye-gene-therapy-hits-mark-in-late-stage-study",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-21T18:59:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/beacon-xlrp-laru-zova-phase-3-study-results/830918/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Beacon claimed the findings represent the first time a treatment for X-linked retinitis pigmentosa, a rare and potentially blinding condition, met its main goal in a pivotal trial.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Beacon says gene therapy succeeds in key trial of rare eye disease XLRP",
        "url": "https://urgent.news/2026/09/21/beacon-says-gene-therapy-succeeds-in-key-trial-of-rare-eye-disease",
        "published": "2026-09-21T06:00:58.000Z"
      },
      {
        "outlet": "Investing.com",
        "title": "Syncona jumps 6% after Beacon gene therapy trial success",
        "url": "https://urgent.news/2026/09/21/syncona-jumps-6-after-beacon-gene-therapy-trial-success",
        "published": "2026-09-21T09:00:41.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}